EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-13.95%
↓ 251% below average
Average (39q)
9.24%
Historical baseline
Range
High:67.90%
Low:-32.95%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -13.95% |
| Q2 2025 | -5.25% |
| Q1 2025 | 35.05% |
| Q4 2024 | 46.81% |
| Q3 2024 | -0.94% |
| Q2 2024 | -1.05% |
| Q1 2024 | 67.90% |
| Q4 2023 | 3.39% |
| Q3 2023 | 10.38% |
| Q2 2023 | 15.51% |
| Q1 2023 | -12.38% |
| Q4 2022 | 39.25% |
| Q3 2022 | -14.09% |
| Q2 2022 | 30.64% |
| Q1 2022 | 11.52% |
| Q4 2021 | 4.94% |
| Q3 2021 | 51.61% |
| Q2 2021 | 2.30% |
| Q1 2021 | 5.26% |
| Q4 2020 | 27.26% |
| Q3 2020 | 24.85% |
| Q2 2020 | -32.50% |
| Q1 2020 | 17.48% |
| Q4 2019 | 18.57% |
| Q3 2019 | -11.91% |
| Q2 2019 | 4.16% |
| Q1 2019 | -9.14% |
| Q4 2018 | -32.95% |
| Q3 2018 | 30.81% |
| Q2 2018 | 43.31% |
| Q1 2018 | -22.11% |
| Q4 2017 | 11.78% |
| Q3 2017 | -9.35% |
| Q2 2017 | 26.74% |
| Q1 2017 | 5.02% |
| Q4 2016 | -24.25% |
| Q3 2016 | 1.80% |
| Q2 2016 | 33.51% |
| Q1 2016 | -17.39% |
| Q4 2015 | 6.86% |